skip nav
National Prevention Information Network
Search Help
Other Searches: Search Organizations | Search Materials | Search Campaign Resources | Search Funding
español
Share Share this page on Twitter Share this page on Facebook Share this page on LinkedIn View more options to share this page E-mail this page to a colleague Print this page


<< Back

News

Study Shows Value of Hepatitis C Therapy for HIV Co-infected Patients with Compensated Cirrhosis

Abstract
Spanish researchers report success in treating HIV- and hepatitis C-coinfected people with compensated cirrhosis—those whose livers are still functioning—with pegylated interferon and ribavirin. Patients who achieved a sustained virologic response (SVR) from hepatitis C treatment had reduced risk of decompensated cirrhosis and liver-related death, according to study authors. SVR essentially means the patient is cured—hepatitis C is undetectable 24 weeks after treatment is completed. To reach these conclusions, the research team reviewed the records of 166 HIV- and hepatitis C-coinfected patients with compensated cirrhosis who received 48 weeks of treatment with pegylated interferon and ribavirin between 2001 and 2011. The team compared progression to decompensated cirrhosis and rates of death between patients who achieved SVR and those who did not. A quarter of the study cohort reached SVR, and 21 percent progressed to decompensated cirrhosis. Of those who achieved SVR, only five percent progressed to decompensated cirrhosis, whereas 27 percent who did not achieve SVR progressed to decompensated cirrhosis. After three years, patients with SVR had a four-percent risk of developing decompensated cirrhosis, and patients without SVR had a 32-percent risk of decompensated cirrhosis. Reaching SVR did not reduce the risk of liver cancer, according to researchers. However, SVR did cut the three-year risk of death compared to those who did not respond to treatment (three percent compared to 20 percent, respectively). Overall, 10 percent of study participants died of liver failure. Hepatitis C causes scarring—cirrhosis—of the liver, which can eventually cause liver failure and death. The full report, “HIV/AIDS: Benefits from Sustained Virological Response to Pegylated Interferon Plus Ribavirin in HIV/HCV-Coinfected Patients with Compensated Cirrhosis,” was published online in the journal Clinical Infectious Diseases (2013;10.1093/cid/cit103).
Source
http://www.aidsmap.com
Date of Publication
03/28/2013
Author
Michael Carter
Article Type
General media
Article Category
Medical News

Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.

cdcnpin.org News Record #61212

<< Back

CDCNPIN.org

Contact Us
About Us
HIV Content Notice
Privacy Policy
Policies & Disclaimers
Site Index
Help Using the CDC NPIN Web Site

CDC NPIN Searches

Search Organizations
Search Materials
Search Funding Opportunities
Search Campaign Resources
Help Using the CDC NPIN Searches

CDC NPIN Resources

hivtest.cdc.gov
m.hivtest.cdc.gov
findtbresources.org
STD Awareness Microsite
findstdtest.org
AIDS Gov Logo and Link CDC Logo and Link